Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
2
Neutral
6
Bullish
6
Bearish
2
Neutral
6
Bullish
38
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Tatva Chintan Pharma Chem Limited is a globally recognized specialty chemical manufacturer. Its core business lies in developing and distributing specialty chemicals like Phase Transfer Catalysts, Structure Directing Agents, and Electrolyte Salts.
In Q3 FY26, the company exhibited significant financial improvement with a 53% revenue growth from the previous year and a dramatic 10,889% increase in PAT.
Tatva Chintan's focus on 'green' chemistry, employing processes like electrolysis and continuous flow chemistry, underscores its commitment to sustainable practices.
The company benefits from a wide international reach, exporting over 62% of its products to countries including the USA, UK, and Germany.
Tatva Chintan's R&D capabilities are robust, with a DSIR-recognized facility and significant investments, facilitating innovative product development and process enhancements.
Chemicals & Petrochemicals
Specialty Chemicals
3,160 Cr
Moderate Risk
96.4
44.3
1.5
4.2
1,603.60
674.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
22.26 | 3,287 Cr | 33.85 | 3.88 | 0.28 | 12.63 | 16.75 | 11.55 | ||
1312.65 | 3,160 Cr | 96.43 | 4.19 | 0.07 | 2.35 | 3.14 | 3.61 | ||
163.35 | 3,051 Cr | 54.84 | 1.72 | 0.82 | 3.14 | 4.35 | 2.64 | ||
452.10 | 3,018 Cr | 20.23 | 2.26 | 0.09 | 11.19 | 13.06 | 6.52 | ||
1613.00 | 2,746 Cr | 22.16 | 6.62 | 0.00 | 29.83 | 37.25 | 13.31 | ||
251.00 | 2,582 Cr | 12.97 | 2.82 | 0.70 | 21.57 | 30.30 | 16.21 | ||
103.00 | 2,541 Cr | -41.46 | 2.56 | 0.00 | 2.35 | 8.04 | -3.07 | ||
| Median: 7 Co. | — | 251.00 | 3,018 Cr | 22.16 | 2.82 | 0.09 | 11.19 | 13.06 | 6.52 |
Upcoming Result Date: May 15, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Tatva Chintan Pharma Chem Ltd (TATVA) is currently trading at 1,355.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Tatva Chintan Pharma Chem Limited is a globally recognized specialty chemical manufacturer. Its core business lies in developing and distributing specialty chemicals like Phase Transfer Catalysts, Structure Directing Agents, and Electrolyte Salts. In Q3 FY26, the company exhibited significant financial improvement with a 53% revenue growth from the previous year and a dramatic 10,889% increase in PAT. Tatva Chintan's focus on 'green' chemistry, employing processes like electrolysis and continuous flow chemistry, underscores its commitment to sustainable practices. The company benefits from a wide international reach, exporting over 62% of its products to countries including the USA, UK, and Germany. Tatva Chintan's R&D capabilities are robust, with a DSIR-recognized facility and significant investments, facilitating innovative product development and process enhancements.
Over the past 52 weeks, Tatva Chintan Pharma Chem Ltd has traded between a low of ₹674.00 and a high of ₹1,603.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Tatva Chintan Pharma Chem Ltd has a market capitalization of approximately 3,160.15. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Tatva Chintan Pharma Chem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 96.43 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,160.15 Cr, Tatva Chintan Pharma Chem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Tatva Chintan Pharma Chem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Tatva Chintan Pharma Chem Ltd is 96.43. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a directive issued by the Indian government under the Essential Commodities Act to manage and prioritize the distribution of natural gas due to disruptions in international LNG supply.
Earnings Call
Tatva Chintan scheduled its Q4/FY26 earnings conference call on 16 May 2026 at 17:00 IST, hosted by ICICI Securities; MD Chintan Shah and CFO Ajesh Pillai to participate and registration/contact details provided.
Earnings Call
Tatva Chintan Pharma Chem will hold an earnings call for the quarter and financial year ended 31 Mar 2026 on Sat, 16 May 2026 at 17:00 IST, hosted by ICICI Securities; MD Chintan Shah and CFO Ajesh Pillai to represent.
Board Meeting Intimation
Board meeting scheduled on 16 May 2026 to consider and approve standalone and consolidated audited financial results for quarter and year ended 31 Mar 2026, and to consider recommending a final dividend; trading window closed.
